Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 29 | ICEECE2012 | Next issue

15th International & 14th European Congress of Endocrinology


The risk and benefits of tight glycaemic control

ea0029s9.1 | The risk and benefits of tight glycaemic control | ICEECE2012

What do type 2 diabetes outcome trials tell us about the CV risks and benefits of intensive glycaemic control

Gerstein Hertzel C.

Diabetes is a strong risk factor for cardiovascular (CV) events, and large epidemiologic studies have repeatedly shown that higher fasting or post-load glucose levels predict a higher incidence of CV events regardless of whether or not diabetes is present. In the UKPDS, targeting near-normal fasting glucose levels in newly diagnosed diabetes with a strategy starting with basal insulin or sulfonylurea reduced the 20-year risk of myocardial infarction and mortality by 15% and 13...

ea0029s9.3 | The risk and benefits of tight glycaemic control | ICEECE2012

Time course of the glucose legacy effect

Holman R.

During the 10-year UK Prospective Diabetes Study (UKPDS) post-trial monitoring period, sustained reductions were seen in the risks of diabetic complications, despite the previously randomised conventional and intensive treatment groups becoming identical with respect to median HbA1c values and glucose-lowering therapies. This continuing benefit of an earlier intervention in people with type 2 diabetes has been termed the ‘legacy effect’. A similar phenomenon seen in ...